Guggenheim Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-21,241
| Closed | -$2.8M | – | 1700 |
|
|
2025
Q1 | $2.8M | Sell |
21,241
-8,878
| -29% | -$1.11M | 0.03% | 551 |
|
|
2024
Q4 | $2.52M | Sell |
30,119
-7,133
| -19% | -$586K | 0.02% | 577 |
|
|
2024
Q3 | $2.73M | Sell |
37,252
-1,017
| -3% | -$76.4K | 0.02% | 720 |
|
|
2024
Q2 | $2.62M | Sell |
38,269
-2,785
| -7% | -$193K | 0.02% | 726 |
|
|
2024
Q1 | $2.84M | Buy |
41,054
+1,245
| +3% | +$85.6K | 0.02% | 761 |
|
|
2023
Q4 | $2.85M | Buy |
39,809
+22,356
| +128% | +$1.29M | 0.02% | 717 |
|
|
2023
Q3 | $909K | Buy |
17,453
+304
| +2% | +$17.7K | 0.01% | 1146 |
|
|
2023
Q2 | $1.09M | Sell |
17,149
-1,453
| -8% | -$90.5K | 0.01% | 1129 |
|
|
2023
Q1 | $1.01M | Buy |
18,602
+6,957
| +60% | +$336K | 0.01% | 1182 |
|
|
2022
Q4 | $616K | Buy |
11,645
+2,288
| +24% | +$115K | 0.01% | 1396 |
|
|
2022
Q3 | $435K | Buy |
9,357
+638
| +7% | +$33.3K | ﹤0.01% | 1534 |
|
|
2022
Q2 | $498K | Sell |
8,719
-664
| -7% | -$37.6K | ﹤0.01% | 1583 |
|
|
2022
Q1 | $574K | Buy |
9,383
+1,692
| +22% | +$87.9K | ﹤0.01% | 1635 |
|
|
2021
Q4 | $402K | Buy |
+7,691
| New | +$323K | ﹤0.01% | 1773 |
|
|
2015
Q4 | – | Sell |
-23,014
| Closed | -$922K | – | 3094 |
|
|
2015
Q3 | $922K | Buy |
+23,014
| New | +$751K | ﹤0.01% | 2141 |
|
Other funds holding ITCI
KIM
HNB